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ABSTRACT: This research considers potential dose increase in target due to cisplatin (Pt)  
concentration and radiation type. Cisplatin concentrations from 0.003  to 120 mM were used. 
Monte-Carlo simulation of Linear accelerator (Elekta Synergy) and X-ray tube (Xstrahl300) 
was carried out using Geant4 and PClab. As the first step of this research, we performed 
simulation of energy spectrum from radiotherapy units (spectrum model). The next step was the 
modeling of linear accelerator head and X-ray tube, and the distribution of dose in the water 
phantom (PDD model). At the second stage, dose changes were investigated in the presence of 
cisplatin in the target (CIS model). The simulation results showed that the dose escalation can 
be caused by photon-capture therapy (PCT). There is a dose enhancement in the volume where 
cisplatin is accumulated. Then higher is concentration, then higher is the effect. However, the 
photon energy increase from 60 to 250 kV and increase of depth of target reduces the effect of 
PCT due the decrease of the photoelectric effect cross-section. Should be noticed, that the 
orthovoltage X-rays energy, listed in the table with results shows higher dose enhancement, than 
the megavoltage photon beam generated from linear acceleration sources. In addition, that the 
dose enhancement factors (DEF) are higher in linac without flattening filter, than in linac with 
flattening filter.  
Keywords: Radiotherapy concepts, Accelerator modelling and simulations (multi-particle 
dynamics; single-particle dynamics), Avalanche-induced secondary effects, Detector modelling 
and simulations I (interaction of radiation with matter, interaction of photons with matter, 
interaction of hadrons with matter, etc), Interaction of radiation with matter, Ionization and 
excitation processes 
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1 Introduction 
Radiation therapy is an important and effective option for treatment of malignant tumors [1]. Actual 
problem of radiotherapy is increasing effectiveness and reducing side effects of the treatment. Binary 
technologies of radiation therapy can be used to improve treatment results. One of the most promising 
technology is contrast-enhanced or “photon-capture” radiotherapy (PCT) [2]. The basic principle of 
PCT is the generation of a large number of the characteristic X-rays and low-energy Auger-electrons 
due to interaction between photons and nuclei of heavy elements (Z ≥ 53). In biological tissue this 
secondary low-energy radiation ionizes nearby atoms and leads to the occurrence of highly active 
radical series, which causes the destruction of the macromolecules of DNA and RNA as well as other 
cell structures. 
The PCT is effective at low X-ray energies where the photoelectric effect dominates (up to about 
200 kV) [3]. Accordingly, the energy escalation of photon beams leads to a gradual decrease the effect 
of the PCT. However, low-energy photons for medium- and deep-seated tumors are limited due to 
their low penetrating ability. But, these orthovoltage X-rays energy may be used in an intraoperative 
therapy or to treatments superficial lesions. And for irradiation of deep-seated tumors, the 
megavoltage photon beams from linear accelerators are widely used, where the Compton effect is 
maximal and the photoelectric effect is minimal. Although the effect of PCT should be low, different 
studies show the escalation of energy in the target volume due to the introduction of dose-enhancing 
agent (DEA) at megavolt photon beams [4,5,6]. Some authors suggest that the observed effect is 
caused by the wide energy spectrum of photon beams, which including the low-energy kilovolt energy 
range. 
In this study the chemotherapeutic drug cisplatin (Cl2H6N2Pt), which contains platinum atoms, 
was taken as DEA. Cisplatin, a widely used cytostatic drug, causes cell cycle arrest, inhibition and 
transcription and, ultimately, apoptosis, i.e. cell death [7]. In the chemoradiation method, the use of 
cisplatin showed that the drug has not only a chemical effect, but also an obvious radiosensitization 
effect in the tumor [8, 9]. 
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In this research we simulated the dependence of dose increase on the DEA concentration at 6 and 
10 MV medical Linac and orthovoltage X-rays radiation using Monte-Carlo simulation by the means 
of Geant4. 
2 Materials and methods  
2.1 Clinical Dosimetry 
The percentage depth dose (PDD) curves were measured on the 6 and 10MV linear accelerator (Elekta 
Synergy, Elekta Ltd.) and X-ray tube (Xstrahl300) with energy 60, 120, 180 and 250 kV (figure 1). 
The PDD of Linear accelerator in a water phantom (Blue Phantom, IBA) using ionization 
chamber CC13(IBA) having a chamber volume was 0.13 cm3, was measured with 1 mm step. The 
source-surface distance (SSD) was 100 cm, the radiation field area was 10×10 cm2. And the PDD in a 
water phantom by 1 mm increments from Xstral300 X-ray tube was measured. 
  
Dose measurements in the energies range 
from 100 kV to 250 kV using an ionization 
chamber PPC40 (IBA) having a chamber 
volume was 0.40 cm3, were carried out. The 
60 kV energy were measured using the SP34 
QA phantom and farmer chamber PTW 
23342 having a chamber volume was 
0.02 cm3. The experimental measurements 
were compared with that calculated using 
Monte-Carlo simulation in water. 
a. Elekta Synergy linac b. Xstrahl300 X-ray tube 
Figure 1. The PDD measurement 
2.2 Monte-Carlo simulation 
Monte-Carlo simulation was carried out using Geant4 version 10 [10] and PClab version 9.9 [11] 
codes to perform the dose calculation in this research. The first step of this research we performed 
simulation of energy spectrum from radiotherapy units (spectrum model). The next step is the 
modeling of head of linear accelerator and X-ray tube and the distribution of dose in the water 
phantom (PDD model). At the second stage, dose changes were investigated in the presence of 
cisplatin in the target (CIS model). A total of 1 x 108 histories was run in the model’s calculation and 
the statistical uncertainty of the simulation was kept less than 1 %. 
2.3 Medical Linac simulation  
Figure 2a shows the spectrum model structure considered in this study. Simulated components 
included: source of electron beams, X-ray target 1mm thick, copper holder below the target 4mm thick 
and sensitive detector 1nm thick. The source was modeled in a vacuum space. Electron beam was 
2 mm in diameter. Accelerated electron beam was bombarded to the tungsten target to produce photon 
beam. For the nominal 6 MV energy photon beam, the incident electron beam with a mean energy of 
6.7 MeV and a Gaussian energy spread of 0.2 MeV were used. The focal spot size was 3.0 mm in the 
crossline direction. For the 10 MV energy photon beam the corresponding values were 10.4 MeV, 
0.3 MeV and 3.0 mm. 
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Based on the manufacturer specifications, we 
simulated the head of the medical linear 
accelerator Elekta Synergy located at the 
Tomsk Regional Oncology Centre. Figure 2b 
present the head structure of the linear 
accelerator considered in this study (PDD 
model). Simulated components included: X-
ray target, Primary conical collimator, X-ray 
beam flattening filter, ionization chamber, 
thin mylar mirror, Multi-Leaf Collimator 
(MLC), Asymmetric jaws. 
a. Spectrum model b. PDD model 
Figure 2. Monte-Carlo simulation of Linac 
The code of PDD simulation from medical linear accelerator was calculation for filtered and 
flattening filter free (FFF) systems. The distance between the accelerator source and  the water 
phantom surface (SSD) was 100 cm. Square field 10x10 cm2 were studied. The voxel size of sensitive 
detector was 0.5x0.5x0.1 cm3. 
2.4 X-ray tube simulation 
In result of interaction between beams of primary particles (electrons) and the tungsten anode of the 
X-ray tube is generated to bremsstrahlung and characteristic radiation. Energy spectrum of generated 
X-ray photon beams in detector 1 nm thick was calculated. Figure 3a shows a simulation of the 
generating x-ray photons (spectrum model). The electron beam is multidirectional point source and 
diameter is equal to 2.00 mm. The anode is located at an angle of 20 degrees. The model includes a 
beryllium window 2 mm thick. 
At the second stage, the interaction of X-ray photons with water phantoms was simulated to 
obtain data on depth-dose distributions. Figure 3b shows a simulation of PDD in water phantom (PDD 
model). The model includes primary filters is half-value layer (HVL), additional filter of various 
thicknesses, conical applicator and water phantom.  
  
Percent depth dose with sensitive ring 
detector was defined 1 cm radius and 
1 mm thick. The PDD with a 1 mm step 
were scored using detector inside a water 
phantom with dimensions was 
41х47,8 см2 at the source to surface 
distance is equal 50 cm for energy more 
than 100 kV and 30 cm for energy up to 
100 kV. The radiation field with a 
transverse size of 10x10 cm2 was used. 
a. Spectrum model b. PDD model 
Figure 3. Monte-Carlo simulation of X-ray tube 
 
The graphic image of the models is presented to figure 4 for Xstral300 X-ray tube and figure 5 
for Elekta Synergy linear accelerator. 
 
 
 
  
 
a. Pclab b. Geant4 a. Pclab b. Geant4 
Figure 4. The graphic  image of Xstral300  
simulation 
Figure 5 The graphic  image of Elekta Synergy 
simulation 
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2.5 Cisplatin simulation (CIS model)  
In the next stage of dose change simulation, we performed with the presence of cisplatin in the target 
volume. Cisplatin concentrations were selected on the basis of acceptable doses that were considered 
in previous works by the authors and higher to evaluate dose changes from cisplatin concentration 
[12,13,14,15,16], while 0,003 mM is the minimum cisplatin concentration during which there is a 
visible effect in radiobiological experiments after X-ray irradiation. Cisplatin was injected into the 
target, which was located at a certain depth of water phantom. A 1 mm, 10 mm, 30 mm and 50 mm 
depths of target location for X-ray tube simulation and 0.5 mm, 50 mm depths of target location for 
linac simulation were considered. This allowed us to observe not only the dependence on DEA 
concentration, but also the dependence on the depth of the target location. The calculations of the 
сisplatin simulation with DEA was carried out while keeping absolutely everyone the parameters of 
the PDD model concept. 
3 Results  
3.1 Spectrum model 
The photon energy spectrum as a function of photon energy for linac is shown in figure 6. The energy 
spectra of incident photons peak were found at 0.511 MV for the maximum nominal energy is 6 and 
10 MV. 
 
  
a) 6MV energy spectrum b) 10MV energy spectrum 
Figure 6. The photon beams energy spectrum after X-ray target 
 
The photon beam energy spectra in the tube voltages including 60, 120, 180 and 250 kV by the 
Geant4 and PClab were calculated. The results are presented in figures 7 to 10. 
 
  
Figure 7. Comparison of X-ray spectra calculation 
using the Geant4 and PClab for 60 kV tube voltage 
Figure 8. Comparison of X-ray spectra calculation 
using the Geant4 and PClab for 120 kV tube voltage 
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Figure 9. Comparison of X-ray spectra calculation 
using the Geant4 and PClab for 180 kV tube voltage 
Figure 10. Comparison of X-ray spectra calculation 
using the Geant4 and PClab for 250 kV tube voltage 
 
The results for these energies showed a similar mathematical differences between Geant4 and 
PClab calculations. The small differences can be associated to the different algorithms and cross-
section files used for different systems. Nevertheless, the results confirmed that spectrum model is 
accurate and can be used for dose distribution calculations in water phantom. 
3.2 Percentage depth dose model 
The PDD obtained by simulations were compared with experimental data obtained with the linear 
accelerator Elekta Synergy in a Tomsk Regional Oncology Center. The PDD for the 10x10 cm2 
irradiation area is shown in figure 11 for 6 MV and in figure 12 for 10 MV. The dose maximum point 
was determined at 1.5 cm depth for 6 MV and 2.2 cm depth for 10MV. The theoretical value of the 
maximum depth of the dose is 1.5 cm for 6 MV and 2.3 cm for 10 MV. 
 
  
a) PClab calculation and measured of PDD b) Geant4 calculation and measured of PDD 
Figure 11. Comparison of PDD calculation with experimentally measured using CC13 for 6 MV linear 
accelerator 
 
  
a) PClab calculation and measured of PDD b) Geant4 calculation and measured of PDD 
Figure 12. Comparison of PDD calculation with experimentally measured using CC13 for 10 MV linear 
accelerator 
 
Figure 13 shows the deviation between simulation and measured results. The mean (maximum) 
deviation was 0.42 % (0.87 %) and 0.47 % (0.80 %) for PClab and Geant4. Figures 14–17 show 
comparison of PDD obtained from experimental measurements using of ionization chamber and 
calculated in the Geant4 and PClab. The curves was 60, 120, 180 and 250 kV tube voltage matched 
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very well within 2 % of PDD values at all depths except 1.21cm depth and 120kV where the 
difference of 2.7 % at PСlab and 3.8 % at Geant4 from experimentally measured. 
 
  
a) 6MV b) 10MV 
Figure 13. The PDD difference simulated by Geant4 and PClab 
  
a) The PDD b) deviation between dose calculation and 
experimentally measured 
Figure 14. Comparison of PDD calculation using the Geant4 and PClab with experimentally measured for 
60 kV tube voltage. 
 
  
a) The PDD b) deviation between dose calculation and 
experimentally measured 
Figure 15. Comparison of PDD calculation using the Geant4 and PClab with experimentally measured for 
120 kV tube voltage. 
 
  
a) The PDD b) deviation between dose calculation and 
experimentally measured 
Figure 16. Comparison of PDD calculation using the Geant4 and PClab with experimentally measured for 
180 kV tube voltage. 
 
- 7 - 
  
a) The PDD b) deviation between dose calculation and 
experimentally measured 
Figure 17. Comparison of PDD calculation using the Geant4 and PClab with experimentally measured for 
250 kV tube voltage. 
3.3 CIS model 
In the next stage the simulation of dose change we performed in the presence of cisplatin in the target 
volume at Linac and X-ray tube irradiation. Table 1–5 presents the dose-enhancing factor (DEF) for 
different depth target location and different cisplatin concentration were calculated by Geant4 and 
PClab. Each of the cases in this table that the no DEA outside the tumor volume was supposed. It's in 
order to provide a clear relationship between the DEA concentration and beam energy. 
The dose enhancement factors (DEF), defined as the ratio of the dose in the tumor volume (  
with DEA to that dose in the tumor without DEA ( : 
 
 
 
In case of linear accelerator simulation the 5 and 50 mm depths of target location and energy 
photon beam to 6 MV and 10 MV were considered. This allowed us to observe not only the 
dependence on agent concentration, but also the dependence on the depth of the target location and 
energy of photons. In addition, linac without a flattening filter (FFF) were considered. The table 1 
shows the dose-enhancing factor for reference points at linacs with flattening filter and flattening filter 
free (FFF).  
As a result, the DEFs calculation for linac does not observe clinically important dose increase. At 
a concentration of 120 mM, a dose increase of up to 7.7 % and 3.1 % is observed for 6 MV and 
10 MV correspondingly. As well as studies of flattening filter free showed  the DEF increase equal to 
8.6 % and 8.9 % when irradiated with a photon beams of 6 and 10 MV (Figure 18). 
 
Table 1. The DEF values for linac in the energy photon beam equal to 6MV and 10MV. 6MV and 10MV – 
Linac with flattening filter; 6MVFFF and 10MVFFF - Linac flattening filter free. 
 
Conc. mM 6MV 10MV 6MV FFF 10MV FFF 
0.5cm PC G4 PC G4 PC G4 PC G4 
12 1.0062 1.0046 1.0000 1.0000 1.0012 1.0042 1.0022 1.0000 
120 1.0200 1.0768 1.0208 1.0314 1.0327 1.0861 1.0241 1.0557 
5cm PC G4 PC G4 PC G4 PC G4 
12 1.0000 1.0047 1.0038 1.000 1.0013 1.0141 1.000 1.0024 
120 1.0659 1.0783 1.0102 1.0205 1.0266 1.0858 1.0216 1.0887 
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a. 6 MV and 6 MVFFFlinacs b. 10 MV and 10 MVFFF linacs 
Figure 18. Comparison of DEF from a linear accelerator at a cisplatin 120 mM concentration  
 
In case of X-ray tube the 1 mm, 10 mm, 30 mm and 50 mm depths of target location and energy 
photon beam equal to 60, 120, 180 and 250 kV were considered. The tables 2-5 shows the DEF for 
reference points. From the tables it can be noted, that the DEF increases for higher values in the 
presence of the cisplatin. There is a dose enhancement in the volume where cisplatin is accumulated. 
The higher is concentration, the higher is the effect. However, the photon energy increase from 60 to 
250 kV reduces the effect of PCT due the decrease of the photoelectric effect cross-section. The 
highest DEF value is observed when irradiated with 60 kV x-ray. 
Table 2. The DEF for 0.1 mm depth target location 
Energy,  kV 60 120 180 250 
Conc., mM PClab Geant4 PClab Geant4 PClab Geant4 PClab Geant4 
0,003 1.0006 1,0012 1,0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,006 1.0005 1,0008 1,0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,009 1.0003 1,0005 1.0020 1.0024 1.0047 1.0029 1.0029 1.0030 
0,012 1.0015 1,0019 1.0025 1.0030 1.0140 1.0084 1.0074 1.0014 
0,3 1.0086 1.0138 1.0121 1.0107 1.0166 1.0133 1.0068 1.0052 
0,6 1.0186 1.0153 1.0130 1.0146 1.0144 1.0156 1.0044 1.0047 
0,9 1.0260 1.0272 1.0233 1.0220 1.0187 1.0213 1,0092 1.0130 
1,2 1.0343 1.0293 1.0252 1.0272 1.0229 1.0257 1.0012 1.0013 
3 1.0851 1.0842 1.0771 1.0772 1.0591 1.0587 1.0302 1.0317 
6 1.1704 1.1702 1.1509 1.1510 1.1033 1.1070 1.0638 1.0643 
9 1.2557 1.2554 1.2238 1.2226 1.1714 1.1733 1.1172 1.1124 
12 1.3396 1.3268 1.2860 1.2916 1.2294 1.2278 1.1491 1,1404 
30 1.8210 1.8162 1.7218 1.7394 1.5489 1.5343 1.3337 1,3256 
60 2.5988 2.5800 2.4155 2.4373 2.0902 2.0780 1.6522 1,6665 
90 3.3372 3.3146 3.1095 3.1361 2.6980 2.6644 1.9760 1,9834 
120 4.0348 4.0013 3.8555 3.9135 3.1744 3.1220 2.2702 2.2866 
 
Table 3. The DEF for 10 mm depth target location 
Energy,  kV 60 120 180 250 
Conc., mM PClab Geant4 PClab Geant4 PClab Geant4 PClab Geant4 
0,003 1.0012 1.0001 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,006 1.0000 1.0001 1.0001 1.0000 1.0000 1.0000 1.0000 1.0000 
0,009 1.0007 1.0014 1.044 1.0000 1.0011 1.0000 1.0000 1.0000 
0,012 1.0000 1.0000 1.0875 1.0000 1.0012 1.0009 1.0000 1.0000 
0,3 1.0148 1.0099 1.0090 1.0092 1.0111 1.0183 1.0035 1.0035 
0,6 1.0176 1.0169 1.0161 1.0150 1.0097 1.0246 1.0084 1.0072 
0,9 1.0293 1.0250 1.0270 1.0244 1.0211 1.0314 1.0175 1.0164 
1,2 1.0305 1.0336 1.0287 1.0307 1.0144 1.0323 1.0126 1.0138 
3 1,0842 1.0860 1.0738 1.0717 1.0565 1.0610 1.0365 1.03512 
6 1.1739 1.1728 1.1519 1.1493 1.1126 1.1216 1.0557 1.0568 
9 1.2611 1.2588 1.2247 1.2237 1.1753 1.1798 1.0998 1.0986 
12 1.3348 1.3438 1.2869 1.2973 1.2165 1.2372 1.1410 1.1407 
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30 1.8477 1.8555 1.7324 1.7385 1.5681 1.5684 1.3198 1.3189 
60 2.6661 2.6910 2.4120 2.4321 2.1225 2.1228 1.6669 1.6670 
90 3.48042 3.5167 3.1560 3.1822 2.6846 2.6771 2.0013 2.0014 
120 4.2669 4.3215 3.8518 3.8963 3.2374 3.2360 2.3130 2.3159 
 
Table 4. The DEF for 10 mm depth target location 
Energy,  kV 60 120 180 250 
Conc., mM PClab Geant4 PClab Geant4 PClab Geant4 PClab Geant4 
0,003 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,006 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,009 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,012 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,3 1.0000 1.0000 1.0044 1.0066 1.0081 1.0183 1.0162 1.0138 
0,6 1.0000 1.0000 1.0115 1.0125 1.0119 1.0123 1.0150 1.0096 
0,9 1.0000 1.0273 1.0187 1.0194 1.0115 1.0283 1.0108 1.0201 
1,2 1.0000 1.0366 1.0198 1.0284 1.0322 1.0398 1.0219 1.0231 
3 1.0577 1.0482 1.0713 1.0723 1.0600 1.0655 1.0246 1.0309 
6 1.1440 1.1303 1.1459 1.1477 1.1197 1.1235 1.0552 1.0544 
9 1.2292 1.2137 1.2138 1.2185 1.1738 1.1713 1.0947 1.0970 
12 1.2995 1.2973 1.2806 1.2997 1.2212 1.2396 1.1428 1.1419 
30 1.8057 1.7924 1.724 1.7293 1.5692 1.5618 1.3570 1.3554 
60 2.5975 2,5899 2.4218 2.4515 2.1234 2.1228 1.6972 1.6990 
90 3.3736 3.3506 3.1367 3.1643 2.6708 2.6697 2.0651 2.0653 
120 4.2406 4.4234 3.8270 3.8598 3.2061 3.2456 2.3870 2.3885 
Table 5. The DEF for 50 mm depth target location 
Energy,  kV 60 120 180 250 
Conc., mM PClab Geant4 PClab Geant4 PClab Geant4 PClab Geant4 
0,003 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,006 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,009 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,012 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 1.0000 
0,3 1.051 1.0064 1.0161 1.0265 1.0209 1.0283 1.0005 1.0098 
0,6 1.0133 1.0175 1.0236 1.03178 1.0145 1.0265 1.0093 1.0127 
0,9 1.0154 1.0314 1.0355 1.0495 1.0231 1.0214 1.0086 1.0083 
1,2 1.0232 1.0387 1.0295 1.0551 1.0226 1.0386 1.0110 1.0122 
3 1.0573 1.0500 1.0839 1.0952 1.0643 1.0702 1.0369 1.0355 
6 1.1400 1.1356 1.1577 1.1646 1.1196 1.1161 1.0859 1.0724 
9 1.2250 1.2203 1.2224 1.2460 1.1769 1.1836 1.1066 1.1136 
12 1.2959 1.2995 1.2890 1.3054 1.2258 1.2390 1.1510 1.1537 
30 1.7933 1.7863 1.7206 1.7360 1.5853 1.58298 1.3432 1.3452 
60 2.5613 2.5647 2.4204 2.4872 2.1475 2.1340 1.6996 1.6911 
90 3.3039 3.3075 3.2333 3.2134 2.7374 2.7056 2.0532 2.0518 
120 4.0713 4.0002 3.946 3.9350 3.2171 3.2306 2.3615 2.3664 
The graph 19 shows a linear increase of DEF at increasing concentration. Based on the 
orthovoltage X-rays energy considered, the highest degree of dose enhancement occurs for 60 kV and 
higher DEA concentration.  
- 10 - 
 
Figure 19. The dependence of DEF on cisplatin concentration at X-ray energies of 60 kV to 250 kV. 
 
Figure 20a presents a comparison between PDD from photon beams with energies of 6 MV, 
1.25 MV(Co-60), 60 kV and 60 kV with cisplatin is shown. Also, figure 20b shows a comparison of 
the PDD between the 6MV, 1.25 MV(Co-60), 250 kV and 250 kV with cisplatin. 
 
  
a. 60 kV with cisplatin b. 250 kV with cisplatin 
Figure 20. Сomparison between PDD from different energy photon beams 
According to the graph, that in the field of DEA accumulation there is a sharp increase in dose 
not only for surface targets, but also for deeply targets located. For example, in the case of the 
cisplatin presence in the target and irradiation by a photon beams with an energy of 250 kV a dose 
accumulation is higher than when irradiated with photon beams with an energy of  MV and 
1.25 MV(Co-60), and even at a depth target location of 5 cm is observed. 
4 Conclusion  
This research considers potential dose increase in target due to cisplatin (Pt) concentration and 
radiation type. In general, Monte-Carlo results showed that dose escalation in target at orthovoltaic x-
ray and megavolt photon beams can be due photon-capture therapy. For X-rays photon beams the DEF 
was higher than for megavoltage photon beam generated from linear acceleration. For 60 kV x-rays, a 
tremendous DEF was seen, ranging of almost 4.3 at the highest Pt concentration. The dose 
enhancement is somewhat less for with increasing energy up to 250 kV. These differences become 
important with very high DEA concentrations to 120 mM in tumor.  
We should also notice, that the DEF is higher in linacs without flattening filter than in linacs with 
flattening filter. For the 6 and 10 MV photon beams with flattening filter the DEF to 1.077 and 1.031 
was seen. As well as 6 and 10 MV without flattening filter - DEF equal to 1.086 and 1.089 was 
observed. It can be assumed that this phenomenon is due to a cause that the flattening filter system 
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absorbs low-energy photon beam. The same time these low-energy photons cause a photoelectric 
effect in FFF systems and corresponding dose increase in the target is observed. 
 Perhaps from the point of view of сlinical significance the DEF values obtained for the 6 and 
10 MV are not important. However, from the point of view of considering the error of dose adjustment 
these factors can be taken into account, for example, with simultaneous chemoradiation treatment or 
the other DEA introduction. 
This way, Monte-Carlo simulation showed that the dose-enhancing factor increases for higher 
values of cisplatin concentrations and lower photon energy.  
 
References: 
[1] R. Baskar, K.A. Lee, R.Yeo, et al., Cancer and Radiation Therapy: Current Advances and Future 
Directions, Int. J. Med. Sci. 9 (2018) 193. 
[2] I.N. Sheino, P.V. Izhevskij, A.A. Lipengolts, et al., Development of binary technologies of radiotherapy of 
malignant neoplasms: condition and problems, Bulletin of Siberian Medicine. 16 (2017) 192. 
[3] V. F. Hohlov. V. N. Kulakov. I. N. Sheino. et al., Method of photon-capture therapy of tumors, Burnazyan 
Federal Medical Biophysical Center. RU Patent No. 2270045 (2006). 
[4] Jain S. Coulter JA. Hounsell AR. et al., Cell-specific radiosensitization by gold nanoparticles at 
megavoltage radiation energies, Int J Radiat Oncol Biol Phys. 79 (2010) 531. 
[5] D. Chithrani, S. Jelveh, F. Jalali, et al., Gold nanoparticles as radiation sensitizers in cancer therapy, 
Radiat Res. 173 (2010) 719. 
[6] R. Berbeco. H. Korideck. W. Ngwa, et al., TU‐C‐BRB‐11: In Vitro Dose Enhancement from Gold 
Nanoparticles under Different Clinical MV Photon Beam Configurations, AAPM. 39 (2012) 3900. 
[7] Gorodetsky R., Levy-Agababa F., Mou X., et al., Combination of cisplatin and radiation in cell culture: 
effect of duration of exposure to drug and timing of irradiation, Int. J. Cancer. 75 (1998) 635. 
[8] Chougule P.B., Suk S., Chu Q.D., Cisplatin as a radiation sensitizer in the treatment of advanced head and 
neck cancers. Results of a phase II study, Cancer. 74 (1994) 1927. 
[9] K. Skov., Interaction of Platinum Drugs With Clinically Relevant X-Ray Doses in Mammalian Cells: A 
Comparison of Cisplatin, Carboplatin, Iproplatin, and Tetraplatin, Int. J. Radiat. Oncol. Biol. Phys. 20 
(1991) 221. 
[10] GEANT4 collaboration, S. Agostinelli et al., GEANT4: A Simulation toolkit, Nucl. Instrum. Meth. 506 
(2003) 250. 
[11] Bespalov V.I., Computer lab (Version 9.9). Program description, program manual, Tomsk Polytechnic 
University, Russia, (2016), pg. 126. 
[12] Yahya Abadi A., Ghorbani M., Mowlavi A. A., et al., A Monte Carlo evaluation of dose enhancement by 
cisplatin and titanocene dichloride chemotherapy drugs in brachytherapy with photon emitting sources, 
Australas Phys Eng Sci Med. 37 (2014) 327. 
[13] Bakhshabadi, M., Ghorbani, M., & Meigooni, A. S., Photon activation therapy: a Monte Carlo study on 
dose enhancement by various sources and activation media. Australas Phys Eng Sci Med. 36 (2013) 301. 
[14] Roeske, J. C., Nuñez, L., Hoggarth, M., et al., Characterization of the Theorectical Radiation Dose 
Enhancement from Nanoparticles. Technol Cancer Res Treat. 6 (2007) 395. 
[15] Hao, Y., Altundal, Y., Moreau, M., et al., Potential for enhancing external beam radiotherapy for lung 
cancer using high-Z nanoparticles administered via inhalation. Phys Med Biol. 60 (2015) 7035. 
- 12 - 
[16] Cho S, Jeong J, Hyeong K., Monte Carlo simulation study on dose enhancement by gold nanoparticles in 
brachytherapy. J Korean Phys Soc. 56 (2010) 1754. 
